Trial Profile
A Randomized, Double-Blind, Multiple Dose, 3-way Crossover, Exploratory Study to Assess the Pharmacodynamic Effects of SAGE-217 Capsules in Healthy Adults Using a 5-hour Phase Advance Model of Insomnia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Zuranolone (Primary)
- Indications Bipolar depression; Dyskinesias; Essential tremor; Insomnia; Major depressive disorder; Parkinson's disease; Postnatal depression; Seizures
- Focus Therapeutic Use
- Sponsors Biogen; Sage Therapeutics
- 09 Oct 2018 Results assessing safety and efficacy of 30 mg and 45 mg doses of SAGE-217, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
- 31 Jan 2018 Primary endpoint has been met. (Sleep efficiency, as determined by polysomnography (PSG)), as reported in a SAGE Therapeutics Media Release
- 31 Jan 2018 Results published in the SAGE Therapeutics Media Release